The sources of economic moats are varied, but few are as powerful as monopoly. Companies that dominate their niche markets with a commanding lead often deliver exceptional long-term financial performance and outstanding stock market returns. If, on top of this, the company’s balance sheet shows almost no long-term debt, its business strength becomes even more impressive.
Intuitive Surgical (ISRG) is precisely such a company. Although this medical device giant has recently faced some challenges, for long-term investors, the stock remains a no-brainer choice.
Intuitive Surgical focuses on the niche of robotic-assisted surgery. Its most famous system is the da Vinci Surgical System, which has been approved for a variety of indications. According to some estimates, this healthcare leader holds a 58% share of the U.S. robotic surgery systems market. However, this metric is somewhat misleading and does not fully reflect Intuitive Surgical’s true dominance.
While there are multiple robotic systems on the market, few can directly compete with the da Vinci system. For example, Stryker’s Mako surgical robotic arm is primarily used for knee and hip replacement surgeries, whereas the da Vinci system is not approved for these indications because it focuses on soft tissue surgery, which excludes the two procedure types mentioned above.
A more accurate measure is this: Intuitive Surgical holds an 86% share of the U.S. market for robotic surgery systems and accessories. Looking at its balance sheet, as of the end of 2025, the company had total liabilities of $2.5 billion against total assets of $20.5 billion. More importantly, its long-term debt accounts for only a small portion of its liabilities. This gives Intuitive Surgical tremendous financial flexibility and the stability to navigate difficult periods with relative ease.
It is worth noting that Intuitive Surgical’s environment is slowly changing. Medical device company Medtronic (MDT) received approval for its Hugo system last year, which will compete with the da Vinci system. Additionally, Johnson & Johnson’s (JNJ) Ottava system is also nearing approval.
Despite these competitive pressures, Intuitive Surgical’s market remains underpenetrated. Beyond its leading market share, the company also benefits from high switching costs—its industry-leading systems have proven over two decades of real-world use to improve patient outcomes. These advantages should enable Intuitive Surgical to maintain its leadership position in its niche for the long term and continue delivering solid financial performance.
Summary: Intuitive Surgical has built a robust economic moat, underpinned by its near-monopoly market position in robotic-assisted surgery (with an 86% share in the U.S. market), virtually no long-term debt, and a strong asset base. For investors seeking stable growth, Intuitive Surgical’s stock remains a worthy consideration, even amid intensifying competition.
